Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation
Creators
- Dirks, Meike1, 2
- Pflugrad, Henning1, 2
- Weissenborn, Karin1, 2
- Buchert, Ralph3
- Wirries, Ann-Katrin2
- Grosse, Gerrit M.2
- Petrusch, Carlotta2
- Schütze, Christian4
- Wilke, Florian4
- Mamach, Martin4
- Hamann, Linda4
- Geworski, Lilli4
- Langer, Laura B.N.5
- Lukacevic, Mario5
- Janssen, Eike5
- Kessler, Mariella5
- Bengel, Frank M.5
- Ross, Tobias L.5
- Berding, Georg5
- Ding, Xiao-Qi6
- Barg-Hock, Hannelore7
- Klempnauer, Jürgen7
- Wetzel, Christian H.8
- Rupprecht, Rainer8
- 1. Integrated Research and Treatment Centre Transplantation (IFB-Tx), Hannover Medical School, Hannover (Germany)
- 2. Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover (Germany)
- 3. Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg (Germany)
- 4. Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover (Germany)
- 5. Department of Nuclear Medicine, Hannover Medical School, Hannover (Germany)
- 6. Institute of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover (Germany)
- 7. General, Visceral and Transplant Surgery, Hannover Medical School, Hannover (Germany)
- 8. Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg (Germany)
Description
Calcineurin inhibitors (CNI) can cause long-term impairment of brain function. Possible pathomechanisms include alterations of the cerebral immune system. This study used positron emission tomography (PET) imaging with the translocator protein (TSPO) ligand F-GE-180 to evaluate microglial activation in liver-transplanted patients under different regimens of immunosuppression. PET was performed in 22 liver-transplanted patients (3 CNI free, 9 with low-dose CNI, 10 with standard-dose CNI immunosuppression) and 9 healthy controls. The total distribution volume (V) estimated in 12 volumes-of-interest was analyzed regarding TSPO genotype, CNI therapy, and cognitive performance. In controls, V was about 80% higher in high affinity binders (n = 5) compared to mixed affinity binders (n = 3). Mean V corrected for TSPO genotype was significantly lower in patients compared to controls, especially in patients in whom CNI dose had been reduced because of nephrotoxic side effect. Our results provide evidence of chronic suppression of microglial activity in liver-transplanted patients under CNI therapy especially in patients with high sensitivity to CNI toxicity.
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-021-05398-wAdditional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 49
- Journal Issue
- 1
- Journal Page Range
- p. 234-245
- ISSN
- 1619-7070
- CODEN
- EJNMA6
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 53030085
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- AFFINITY; BRAIN; COMPARATIVE EVALUATIONS; FLUORINE 18; GENOTYPE; IMAGE PROCESSING; IMMUNOSUPPRESSION; IMMUNOTHERAPY; KIDNEYS; LIVER; MACROPHAGES; NMR IMAGING; POSITRON COMPUTED TOMOGRAPHY; PROTEINS; RADIOPHARMACEUTICALS; RELAXATION TIME; SIDE EFFECTS; TOXICITY; TRANSPLANTS; WEIGHTING FUNCTIONS
- Descriptors DEC
- ANIMAL CELLS; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; CENTRAL NERVOUS SYSTEM; COMPUTERIZED TOMOGRAPHY; CONNECTIVE TISSUE CELLS; DIAGNOSTIC TECHNIQUES; DIGESTIVE SYSTEM; DRUGS; EMISSION COMPUTED TOMOGRAPHY; EVALUATION; FLUORINE ISOTOPES; FUNCTIONS; GLANDS; HOURS LIVING RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; MATERIALS; MEDICINE; NANOSECONDS LIVING RADIOISOTOPES; NERVOUS SYSTEM; NUCLEI; ODD-ODD NUCLEI; ORGANIC COMPOUNDS; ORGANS; PHAGOCYTES; PROCESSING; RADIOACTIVE MATERIALS; RADIOISOTOPES; SOMATIC CELLS; THERAPY; TOMOGRAPHY
Optional Information
- Notes
- Themed sections on Alpha Particles Therapy and TSPO Imaging